Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1993 Apr;91(4):1753–1760. doi: 10.1172/JCI116385

Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.

R Donghi 1, A Longoni 1, S Pilotti 1, P Michieli 1, G Della Porta 1, M A Pierotti 1
PMCID: PMC288155  PMID: 8473515

Abstract

The p53 gene was analyzed in tumor specimens obtained from 52 patients with various types of carcinoma of the thyroid gland by a combined molecular and immunocytochemical approach. The histologic types included 37 well-differentiated papillary and follicular carcinomas, 8 poorly differentiated, and 7 undifferentiated carcinomas. The p53 gene was shown to be unaffected in all differentiated tumors by single-strand conformation polymorphism analysis. However, in two out of eight (25%) of poorly differentiated carcinomas and five out of seven (71%) undifferentiated carcinomas, p53 mutations were identified and subsequently characterized by DNA sequencing. One undifferentiated carcinoma displayed two areas with varying degrees of differentiation. The comparative analysis of the p53 gene, in both the more and the less differentiated area of this tumor, clearly showed that the p53 mutation was confined to the latter component of the tumor specimen. These results indicate that mutations of the p53 gene are associated with the most aggressive histologic types of thyroid tumors, such as the undifferentiated carcinoma and, to a certain extent, the poorly differentiated carcinoma, and that the alterations of this gene represent a late genetic event in human thyroid carcinogenesis.

Full text

PDF
1753

Images in this article

1754Image
on p.1754
1754Image
on p.1754
1754Image
on p.1754
1755Image
on p.1755
1755Image
on p.1755
1755Image
on p.1755
1755Image
on p.1755
1755Image
on p.1755
1756Image
on p.1756
1758Image
on p.1758
1758Image
on p.1758
1759Image
on p.1759

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bongarzone I., Pierotti M. A., Monzini N., Mondellini P., Manenti G., Donghi R., Pilotti S., Grieco M., Santoro M., Fusco A. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene. 1989 Dec;4(12):1457–1462. [PubMed] [Google Scholar]
  2. Carbone D., Chiba I., Mitsudomi T. Polymorphism at codon 213 within the p53 gene. Oncogene. 1991 Sep;6(9):1691–1692. [PubMed] [Google Scholar]
  3. Carcangiu M. L., Zampi G., Rosai J. Poorly differentiated ("insular") thyroid carcinoma. A reinterpretation of Langhans' "wuchernde Struma". Am J Surg Pathol. 1984 Sep;8(9):655–668. doi: 10.1097/00000478-198409000-00005. [DOI] [PubMed] [Google Scholar]
  4. Chiba I., Takahashi T., Nau M. M., D'Amico D., Curiel D. T., Mitsudomi T., Buchhagen D. L., Carbone D., Piantadosi S., Koga H. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene. 1990 Oct;5(10):1603–1610. [PubMed] [Google Scholar]
  5. Frigo B., Scopsi L., Patriarca C., Rilke F. Silver enhancement of nickel-diaminobenzidine as applied to single and double immunoperoxidase staining. Biotech Histochem. 1991;66(3):159–167. doi: 10.3109/10520299109110572. [DOI] [PubMed] [Google Scholar]
  6. Gaidano G., Ballerini P., Gong J. Z., Inghirami G., Neri A., Newcomb E. W., Magrath I. T., Knowles D. M., Dalla-Favera R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5413–5417. doi: 10.1073/pnas.88.12.5413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gannon J. V., Greaves R., Iggo R., Lane D. P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 1990 May;9(5):1595–1602. doi: 10.1002/j.1460-2075.1990.tb08279.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gerdes J., Becker M. H., Key G., Cattoretti G. Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol. 1992 Sep;168(1):85–86. doi: 10.1002/path.1711680114. [DOI] [PubMed] [Google Scholar]
  9. Greco A., Pierotti M. A., Bongarzone I., Pagliardini S., Lanzi C., Della Porta G. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene. 1992 Feb;7(2):237–242. [PubMed] [Google Scholar]
  10. Grieco M., Santoro M., Berlingieri M. T., Melillo R. M., Donghi R., Bongarzone I., Pierotti M. A., Della Porta G., Fusco A., Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990 Feb 23;60(4):557–563. doi: 10.1016/0092-8674(90)90659-3. [DOI] [PubMed] [Google Scholar]
  11. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  12. Ito T., Seyama T., Mizuno T., Tsuyama N., Hayashi T., Hayashi Y., Dohi K., Nakamura N., Akiyama M. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 1992 Mar 1;52(5):1369–1371. [PubMed] [Google Scholar]
  13. Johnson T. L., Lloyd R. V., Thompson N. W., Beierwaltes W. H., Sisson J. C. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol. 1988 Jan;12(1):22–27. doi: 10.1097/00000478-198801000-00003. [DOI] [PubMed] [Google Scholar]
  14. Klein R., Jing S. Q., Nanduri V., O'Rourke E., Barbacid M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell. 1991 Apr 5;65(1):189–197. doi: 10.1016/0092-8674(91)90419-y. [DOI] [PubMed] [Google Scholar]
  15. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  16. Mazars R., Pujol P., Maudelonde T., Jeanteur P., Theillet C. p53 mutations in ovarian cancer: a late event? Oncogene. 1991 Sep;6(9):1685–1690. [PubMed] [Google Scholar]
  17. Mizukami Y., Noguchi M., Michigishi T., Nonomura A., Hashimoto T., Otakes S., Nakamura S., Matsubara F. Papillary thyroid carcinoma in Kanazawa, Japan: prognostic significance of histological subtypes. Histopathology. 1992 Mar;20(3):243–250. doi: 10.1111/j.1365-2559.1992.tb00963.x. [DOI] [PubMed] [Google Scholar]
  18. Murray V. Improved double-stranded DNA sequencing using the linear polymerase chain reaction. Nucleic Acids Res. 1989 Nov 11;17(21):8889–8889. doi: 10.1093/nar/17.21.8889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ordóez N. G., El-Naggar A. K., Hickey R. C., Samaan N. A. Anaplastic thyroid carcinoma. Immunocytochemical study of 32 cases. Am J Clin Pathol. 1991 Jul;96(1):15–24. doi: 10.1093/ajcp/96.1.15. [DOI] [PubMed] [Google Scholar]
  20. Sakamoto A., Kasai N., Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer. 1983 Nov 15;52(10):1849–1855. doi: 10.1002/1097-0142(19831115)52:10<1849::aid-cncr2820521015>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  21. Santoro M., Carlomagno F., Hay I. D., Herrmann M. A., Grieco M., Melillo R., Pierotti M. A., Bongarzone I., Della Porta G., Berger N. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest. 1992 May;89(5):1517–1522. doi: 10.1172/JCI115743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Serra A., Gaidano G. L., Revello D., Guerrasio A., Ballerini P., Dalla Favera R., Saglio G. A new TaqI polymorphism in the p53 gene. Nucleic Acids Res. 1992 Feb 25;20(4):928–928. doi: 10.1093/nar/20.4.928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Shi S. R., Key M. E., Kalra K. L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991 Jun;39(6):741–748. doi: 10.1177/39.6.1709656. [DOI] [PubMed] [Google Scholar]
  24. Shi Y. F., Zou M. J., Schmidt H., Juhasz F., Stensky V., Robb D., Farid N. R. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res. 1991 May 15;51(10):2690–2693. [PubMed] [Google Scholar]
  25. Sidransky D., Mikkelsen T., Schwechheimer K., Rosenblum M. L., Cavanee W., Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature. 1992 Feb 27;355(6363):846–847. doi: 10.1038/355846a0. [DOI] [PubMed] [Google Scholar]
  26. Soussi T., Caron de Fromentel C., May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene. 1990 Jul;5(7):945–952. [PubMed] [Google Scholar]
  27. Suarez H. G., du Villard J. A., Severino M., Caillou B., Schlumberger M., Tubiana M., Parmentier C., Monier R. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene. 1990 Apr;5(4):565–570. [PubMed] [Google Scholar]
  28. Venkatesh Y. S., Ordonez N. G., Schultz P. N., Hickey R. C., Goepfert H., Samaan N. A. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 1990 Jul 15;66(2):321–330. doi: 10.1002/1097-0142(19900715)66:2<321::aid-cncr2820660221>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  29. Williams E. D. The aetiology of thyroid tumours. Clin Endocrinol Metab. 1979 Mar;8(1):193–207. doi: 10.1016/s0300-595x(79)80017-1. [DOI] [PubMed] [Google Scholar]
  30. Wright P. A., Lemoine N. R., Goretzki P. E., Wyllie F. S., Bond J., Hughes C., Röher H. D., Williams E. D., Wynford-Thomas D. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Oncogene. 1991 Sep;6(9):1693–1697. [PubMed] [Google Scholar]
  31. Wright P. A., Williams E. D., Lemoine N. R., Wynford-Thomas D. Radiation-associated and 'spontaneous' human thyroid carcinomas show a different pattern of ras oncogene mutation. Oncogene. 1991 Mar;6(3):471–473. [PubMed] [Google Scholar]
  32. Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemistry? J Pathol. 1992 Apr;166(4):329–330. doi: 10.1002/path.1711660402. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES